Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months
V Nguyen, A Vaze, S Fraser-Bell, J Arnold… - Ophthalmology …, 2019 - Elsevier
Purpose Currently, little evidence supports the safety of suspending vascular endothelial
growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD).
We assessed the outcomes of eyes in which this seems to have been attempted. Design
Observational study from a prospectively designed database. Participants Eyes enrolled in
the Fight Retinal Blindness! registry of nAMD treatment outcomes were considered to have
suspended treatment if they had a 3-month or longer documented period of inactivity of the …
growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD).
We assessed the outcomes of eyes in which this seems to have been attempted. Design
Observational study from a prospectively designed database. Participants Eyes enrolled in
the Fight Retinal Blindness! registry of nAMD treatment outcomes were considered to have
suspended treatment if they had a 3-month or longer documented period of inactivity of the …
